Uridine phosphorylase inhibitors to treat or prevent pulmonary disease
US12194043B2 · kind B2 · utility
0Cited by
16References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 7, 2021 |
| Grant date | Jan 14, 2025 |
| Priority date | — |
| Expiry date | Jul 7, 2041 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P11/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to compositions, formulations, and methods for treating pulmonary disorders having fibrosis as part of the underlying pathology, such as IPF and ARDS, by administration of a UPase inhibitor, with or without supplemental UR, a UR prodrug, or a UR mimetic to a subject in need thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.